Ranolazine Loading to Prevent PCI-induced Myocardial Injury

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT01491061

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01491061
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01491061. Randomized; triple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ranolazine Loading to Prevent PCI-induced Myocardial Injury
Acronym
TWILIGHT
Intervention (Drug)
Ranolazine
Intervention (Drug)
Placebo
Lead sponsor
University of Roma La Sapienza (class: other)

Record details

Record id
cardio:ct-nct01491061
Content hash
244bf238e7a8282f5ef35845bb0a7fb6df8a8396e4858b51e9ea9e6b2a3a9ae0